Health Care & Life Sciences » Biotechnology | Hemispherx Biopharma Inc.

Hemispherx Biopharma Inc.

Hemispherx Biopharma Inc.
Stock Exchange NYSE
EPS
$9.43
Market Cap
$9.02 M
Shares Outstanding
2.2 M
Public Float
47.63 M
Hemispherx Biopharma Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
47.25 M
Public Float
46.11 M

Profile

Address
2117 South West Highway 484
Ocala Florida 32801
United States
Employees -
Website http://www.hemispherx.net
Updated 09/14/2018
Hemispherx Biopharma, Inc. operates as a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon.

Financials

View All
Created with Highcharts 5.0.14Hemispherx Biopharma Inc.Net Income. Fiscal year is January-December. All values USD Thousands.16 22516 22517 45017 45015 23015 2307 5027 5028 2598 2592013201420152016201705k10k15k20k
Created with Highcharts 5.0.14Hemispherx Biopharma Inc.Sales/Revenue. Fiscal year is January-December. All values USD Thousands.1501501971971331339292437437201320142015201620170100200300400500

Thomas Kenwood Equels
Executive Vice Chairman, President & CEO
William M. Mitchell
Chairman